Altria-Philip Morris Tie-Up: Positives and Negatives

Altria-Philip Morris Tie-Up: Positives and Negatives

Investors aren't applauding the potential merger, but one analyst points out what the advantages for both parties would be.

Philip Morris Confirms It's in Merger Talks With Altria

Philip Morris Confirms It's in Merger Talks With Altria

Tobacco giant Philip Morris International confirms it is in discussions with rival cigarette maker Altria Group in a potential all-stock deal that it calls 'a merger of equals.'

Luxury Retailer Farfetch Denies It Will Rescue Barneys from Bankruptcy

Luxury Retailer Farfetch Denies It Will Rescue Barneys from Bankruptcy

Farfetch denies it will be acquiring Barneys New York, which filed for bankruptcy earlier in August.

WageWorks Rejects Takeover Offer From Mansa, Will Proceed With HealthEquity Deal

WageWorks Rejects Takeover Offer From Mansa, Will Proceed With HealthEquity Deal

WageWorks receives an unsolicited and non-binding letter of interest from Mansa but says it 'unanimously rejects' the offer.

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Otezla Price Under Microscope -- but Look Closely and It Checks Out

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Alexion Shares Decline in Wake of Amgen's Deal for Otezla

Recent speculation that the biotech giant would buy Alexion had boosted ALXN's shares. But Amgen just agreed to lay out $13.4 billion for Celgene's psoriasis drug.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen Charts Indicate Shares Want to Work Their Way Higher Longer Term

Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.

PDC Energy to Buy SRC Energy in $1.7 Billion Stock-and-Debt Deal

PDC Energy to Buy SRC Energy in $1.7 Billion Stock-and-Debt Deal

PDC Energy reaches an agreement to acquire SRC Energy in an all-stock deal valued at about $1.7 billion, including debt.

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen Adds Celgene's Otezla to Bolster Pipeline at Pricey Valuation

Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.